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notable differences in episode costs and in the use of other classes
of prescription drugs. CONCLUSIONS: The benchmark data
presented here rests on a stable and credible foundation, and
offer a unique and integrated perspective on the care of MS.
While the information presented here may generate more ques-
tions than it can precisely answer, it has genuine value as a high-
level starting point for more deﬁnitive pharmacoeconomic
studies.
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OBJECTIVE: To evaluate the patient characteristics, diagno-
sis/comorbidities, and real-world dosing among Medicaid
patients prescribed topiramate. METHODS: A retrospective
database analysis was conducted using South Carolina (SC) and
Texas (TX) ambulatory Medicaid claims from October 1, 2003
through December 31, 2004. Patients were required to have ≥2
topiramate prescriptions during the study period and were
required to be <65 years old. Patients were categorized into four
cohorts: 1) epilepsy only; 2) migraine only; 3) epilepsy and
migraine; and 4) neither epilepsy nor migraine. A comprehen-
sive set of additional diagnoses, based on literature search,
Micromedex compendium, and USPDI, was also examined.
Demographic characteristics and average daily dose of topira-
mate (ADDoT) were summarized using descriptive statistics.
RESULTS: During 2004, there were 2216 patients in SC Med-
icaid and 4766 patients in TX Medicaid meeting the study selec-
tion criteria. Mean (SD) age was 29.9 (15.9) in SC, and 27.1
(16.1) in TX. In SC, the cohort classiﬁcation percentages were
32.3% (epilepsy only), 29.7% (migraine only), 10.7% (epilepsy
and migraine), and 27.3% (neither epilepsy nor migraine). In
TX, the cohorts were 39.6% (epilepsy only), 16.4% (migraine
only), 9.2% (epilepsy and migraine), and 34.9% (neither
epilepsy nor migraine). In the neither epilepsy nor migraine
cohort, the most common diagnoses were bipolar disorder and
depression. Mean (SD) ADDoT in the epilepsy only cohort was
205.2mg (157.5) [SC], 239.6mg (182.1) [TX]. The ADDoT in
the migraine only cohort was 136.5mg (112.6) [SC], 150.0mg
(129.6) [TX]. CONCLUSION: This is the ﬁrst study to examine
patterns of topiramate use in two Medicaid populations. It
revealed that topiramate was prescribed in a young population,
and approximately 70% of patients had an epilepsy and/or
migraine diagnosis.
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OBJECTIVES: The purpose of this study was to determine the
cost of nursing home care for patients with Parkinson’s disease
using retrospective database analysis. METHODS: The Medical
Expenditures Panel Survey Nursing Home Component (MEPS-
NHC) was used to estimate the cost of nursing home care for
patients with Parkinson’s disease. A total of 5899 patients in 815
nursing facilities were sampled in the MEPS-NHC. Since the
MEPS-NHC is only accessible through the Center for Financing,
Access and Cost Trends (CFACT) located in Rockville, MD, it
was necessary to apply to the CFACT Data Center and request
access to the data. In order to analyze the MEPS-NHC data it
was necessary to link multiple ﬁles together to create one ﬁle for
analysis. The person level ﬁles (NHC001P, NHC-002, and NHC-
007) were merged using the original person identiﬁcation
number (ORIGPERSID) and this resulted in the creation of one
person level ﬁle. The facility level ﬁles (NHC-001F and NHC-
003) were merged using the sample facility identiﬁcation number
(SFID) and this resulted in one facility level ﬁle. The SFID
appeared in NHC-002 of the person level ﬁles and was used as
the common variable to merge the single person level ﬁle and
facility level ﬁles that were created into one ﬁnal merged ﬁle.
RESULTS: Using the patient weights assigned by MEPS-NHC,
these 208 patients represented 99,989 Parkinson’s patients in
nursing home facilities in the United States. The weighted total
for nursing home costs for patients with Parkinson’s disease in
1996 was $3.2 billion. The weighted total nursing home cost for
males in 1996 was $1.14 billion and for females the weighted
total cost was $2.08 billion. CONCLUSIONS: The estimate pre-
sented here highlights the need for future studies that identify the
cost of nursing home care for other chronic disease states.
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OBJECTIVE: One of the disadvantages of propensity score
matching is failure to apply on continuous variables. This paper
proposes a method to control for selection bias when propensity
score matching technique is not applicable. METHODS: The
proposed method ﬁrst uses continous variable rather than a
binary variable in the ﬁrst stage estimation. Since non-treated
patients will have zero use and treated patient will have positive
use of treatment. Tobit regression is proposed to estimate treat-
ment use. Second, using Tobit residuals in the second stage equa-
tion to estimating health care cost or utility, we showed that
selection bias due heterogeneity of patients are removed.
RESULTS: Market Scan data were used to estimate total health
care expenditures of migraine patients treated by triptan.
Number of triptan scripts is used to do matching rather than
binary variable. Mean value for triptan scripts for treated
patients were 4.37. After certain inclusion and exclusion criteria
43,776 migraine patient with triptan used created our analytic
samples. We used same number of control patients. After con-
trolling for demographic and clinical factors, we add Tobit resid-
uals as an additional variable in to our heath expenditure model.
Signiﬁcance of coefﬁcient on residuals showed that selection bias
exists and failure to account for that bias would yield spurious
results. CONCLUSIONS: Propensity Score matching may not be
applied in certain situations. This paper examined a case where
selection was due to continuous variable and proposed and
applied a technique under this circumstance.
